Skip to main content

Table 3 Incidence of treatment emergent adverse events (TEAEs) and adverse events (AEs) patients treated with ASAQ

From: Clinical tolerability of artesunate-amodiaquine versus comparator treatments for uncomplicated falciparum malaria: an individual-patient analysis of eight randomized controlled trials in sub-Saharan Africa

Sign or symptom Total number of patients Prevalence at enrolment TEAE AE AE vs TEAE
n Incidence n Incidence Relative difference
Gastro-intestinal Anorexia 1279 47% 217 17% 551 43% 154%
Abdominal 740 46% 66 9% 202 27% 206%
  Vomiting 1277 34% 188 15% 392 31% 108%
  Diarrhoea 1278 20% 214 17% 315 25% 47%
  Nausea 726 18% 22 3% 107 15% 386%
Neurological Headache 736 46% 27 4% 132 18% 388%
  Dizziness 519 2% 3 1% 15 3% 399%
  Tinnitus 200 1% 1 1% 1 1% 0%
Dermatological Pruritus 756 26% 141 19% 192 25% 36%
  Skin symptom 759 24% 97 13% 118 16% 22%
Other Cough 759 69% 248 33% 371 49% 50%
  Weakness 1119 59% 176 16% 470 42% 167%
  Myalgia 216 32% 17 8% 21 10% 24%
  Jaundice 759 2% 4 1% 4 1% 0%
  1. * The total number of patients was different since different signs or symptoms were screened across the studies.